Garuda - Garba Rujukan Digital

Article Per Year (5 Year)

p-Index From 2020 - 2025

0.61

P-Index

This Author published in this journals

All Journal Medical Journal of Indonesia Indonesian Journal of Cancer Radioterapi & Onkologi Indonesia Narra J

Soehartati Gondhowiardjo

Department of Radiology, Faculty of Medicine Universitas Indonesia/Dr. Cipto Mangunkusumo Hospital, Jakarta

Author-ID : 270023

Biochemistry, Genetics & Molecular Biology Education Health Professions Immunology & microbiology Medicine & Pharmacology Physics Public Health Other

Published : 7 Documents Claim Missing Document

Claim Missing Document

Articles

Evaluation of EBV-LMP1 as prognostic indicator of nasopharyngeal carcinoma in Indonesian patients Kurniawan, A. N.; Kodariah, Ria; Elisabeth, Meryanne; Roezin, Averdi; Gondhowiardjo, Soehartati
Medical Journal of Indonesia Vol 11, No 2 (2002): April-June
Publisher : Faculty of Medicine Universitas Indonesia

Forty eight cases of nasopharyngeal carcinoma patients who had been treated with radiotherapy were analysed for the expression ofÂ EBER in the nucleus of the tumor cells by in situ hybridization technique. EBER was expressed in 69% of the cases. HistologicÂ specimens positive for EBER were then examined for the expression of EBV-LMP1 by immunohistochemistry, which showed 68%Â positivity. Clinical staging of 48 cases and radiation response of 32 cases were collected. Data of up to 2 years of survival of 16 casesÂ were obtained through postal and phone communication. Statistical analysis showed that the Working Formulation histologicÂ classification of NPC correlated significantly with radiation response. The expression of EBV-LMP1 was correlated significantly withÂ the survival of the patients. Thus EBV-LMP1 which has been shown to possess influence on lymphoid and epithelial cells,Â clinicopathologically proved to have a function as prognostic indicator. (Med J Indones 2002; 11: 81-6)Keywords:Â nasopharyngeal carcinoma, histopathologic types, EBER, EBV- lmp1, survival

Stereotactic Ablative Body Radiotherapy (SABR) in The Management Spinal Metastases: A Brief Overview* KODRAT, HENRY; GONDHOWIARDJO, SOEHARTATI
Indonesian Journal of Cancer Vol 11, No 1 (2017): Jan-Mar
Publisher : Indonesian Journal of Cancer

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (660.549 KB)

It is well known that radiotherapy provides successful pain relief in bone metastases. Advancements in imaging and radiotherapy delivery technology have enabled safe delivery of higher dose radiotherapy, which will produce more durable tumor control. Over the last decades stereotactic radiosurgery (SRS), which delivers high dose radiation, has been successfully used for the treatment of intracranial lesions. The good results obtained in SRS have led to development of extra cranial stereotactic radiosurgery known as stereotactic ablative body radiotherapy (SABR). This review paper enlightens indication, target definition, efficacy and toxicity in spinal SABR.ABSTRAK Radioterapi telah terbukti sebagai modalitas yang dapat menghilangkan nyeri pada metastases tulang. Kemajuan dalam teknologi pencitraan dan pemberian radioterapi telah memungkinkan pemberian radioterapi dosis tinggi dengan aman, di mana hal ini dapat meningkatkan kontrol lokal. Selama dekade terakhir ini, stereotactic radiosurgery (SRS) yang memberikan radiasi dosis tinggi dinyatakan bermanfaat untuk tatalaksana berbagai kelainan intrakranial. Hasil cukup memuaskan yang diperoleh SRS mendorong untuk dikembangkan stereotactic radiosurgery ekstrakranial yang kemudian dikenal sebagai stereotactic ablative body radiotherapy (SABR). Tinjauan pustaka ini menjelaskan indikasi, target radiasi, efektivitas, dan efek samping pada prosedur SABR spinal.

Papillary and follicular thyroid carcinoma: Impact of treatment in 44 patients at the Cipto Mangunkusumo Hospital Badri, Cholid; Kuswanto, Olivia; Gondhowiardjo, Soehartati; Astarto, Bangun; Kusumawijaya, Kahar
Medical Journal of Indonesia Vol 3, No 1 (1994): January-March
Publisher : Faculty of Medicine Universitas Indonesia

[no abstract available]

Breast-conserving treatment versus mastectomy in T1-2N0 breast cancer: which one is better for Indonesian women? Nugroho, Rafiq S.; Soediro, Ratnawati; Siregar, Nuryati C.; Djoerban, Zubairi; Poetiray, Evert D.C.; Gondhowiardjo, Soehartati
Medical Journal of Indonesia Vol 21, No 4 (2012): November
Publisher : Faculty of Medicine Universitas Indonesia

Background: This study aimed to compare the treatment outcomes between the use of breast-conserving treatment (BCT) and mastectomy for T1-2N0 breast cancer patients.Methods: This study retrospectively reviewed T1-2N0 breast cancer patients who received treatment between January 2001 and December 2010 at Department of Radiotherapy Cipto Mangunkusumo Hospital and Jakarta Breast Center. The endpoints of this study were overall survival (OS), local recurrence (LR), contra-lateral breast cancer (CBC), distant metastasis (DM), and disease-free survival (DFS).Results: Among the 262 eligible patients, 200 (76.3%) patients underwent BCT while 62 (23.7%) patients underwent mastectomy. There were no differences between BCT and mastectomy groups in 5-Y OS (88.2% vs 86.7%, p = 0,743), LR (7.4% vs 2.7%, p = 0.85), CBC (3.4% vs 5.3%, p = 0.906), DM (17.7% vs 37.7%, p = 0.212), and DFS (78.5% vs 60.7%, p = 0.163). In multivariate analysis, grade 3 was associated with worse OS (HR 2.79; 95% CI 1.08 – 7.21, p = 0.03) and DFS (HR 2.32; 95% CI 1.06 – 5.06). Premenopausal women were associated with decreased risk of DM (HR 0.37; 95% CI 0.17 – 0.80) and DFS (HR 0.38; 95% CI 0.19 – 0.78).Conclusion: BCT and mastectomy showed similar outcome in terms of OS, LR, CBC, DM, and DFS. (Med J Indones. 2012;21:220-4)Keywords: Breast-conserving treatment, mastectomy, outcomes

Epidemiology of 10 Cancer Types in Indonesia: A Multicenter Study Jayalie, Vito Filbert; Gondhowiardjo, Soehartati; Kotambunan, Charity; Apriantoni, Riyan; Manuain, Donald Arinanda; Hawariy, Salik; Prajogi, Gregorius Ben; Permata, Tiara Bunga Mayang; Handoko, Handoko; Munandar, Arie; Sekarutami, Sri Mutya
Radioterapi & Onkologi Indonesia Vol 14, No 1 (2023): Volume 14 No.1 July 2023
Publisher : Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia (PORI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32532/jori.v13i2.161

Cancer remains one of the largest contributors to the burden of health and mortality around the world. A study estimated 19.3 million new cases of cancer in the year 2020. GLOBOCAN 2020 provides a list of the most common cancers in the world which are prostate, lung, and colorectal cancers in men and breast, colorectal, and lung cancer in women. Naturally, different sociodemographic and geographic characteristics will cause disparities in these estimates. Since valid epidemiological data on cancer types in Indonesia remains unavailable, this study intended to provide data on the pattern of distribution of the 10 most common cancer types amongst various hospitals in Indonesia. This was achieved through the collection of registries and/or medical records that were obtained from March to September 2022. The data were then sorted and analyzed using SPSS 20.0. The resulting epidemiological data in multi-centers in Indonesia yielded a similar top 10 most common cancers trend with the GLOBOCAN 2020 worldwide incidence, although some differences were seen. A universal similarity that is found amongst different databases seems to be the prevalence of breast cancers, which always ‘champions’ all databases as the most common cancers among women. This provides a reflection for policy and decision makers for their prompt action to promote the prevention, diagnosis, and treatment of cancers in Indonesia, especially breast cancers.

Treatment acceptance and its associated determinants in cancer patients: A systematic review Novirianthy, Rima; Syukri, Maimun; Gondhowiardjo, Soehartati; Suhanda, Rachmad; Mawarpury, Marty; Pranata, Agung; Renaldi, Teuku
Narra J Vol. 3 No. 3 (2023): December 2023
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v3i3.197

Treatment recommendations for cancer patients are carried out according to clinical assessment, type and stage of cancer and treatment guidelines. However, many patients do not accept the recommendations. This raises obstacles in managing of cancers, which not only affects the patients, but also the family and people around the patients. This problem could increase morbidity, mortality and recurrence rate, which might result in lower quality of life. Since this condition is a complex problem, there is necessity to explore and determine various determinants from different levels. The aim of this systematic review was to explore the acceptances of cancer treatments among cancer patients and its associated determinants. Articles published from 2010 to 2023 were searched in four databases: ScienceDirect, Medline, Google Scholar and PubMed. Articles written in English and focussing on three main cancer treatments (surgery, chemotherapy and radiotherapy) were eligible. A narrative approach was used and the data were analysed into selected themes. Data suggest that several factors influence patient acceptance for cancer therapy including sociodemographic, economic and spiritual cultural backgrounds; patient knowledge and perceptions; community support, as well as policy and availability of health facilities. The determinants consist of individual, interpersonal, institutional, community and public policy level and interaction between levels are contributing to cancer treatment acceptance. In conclusion, cancer treatment acceptance remains a problem in particular in low middle income countries. In addition, the data on radiotherapy referral acceptance were limited and needed further study.

Spectrum of rare EGFR mutations in Indonesian lung adenocarcinoma: Findings from an 8-year analysis of 4,778 cases highlighting the need for advanced targeted therapies Heriyanto, Didik S.; Trisnawati, Ika; Rachmadi, Lisnawati; Tenggara, Jeffry B.; Lau, Vincent; Gunawan, Andrew N.; Halim, Brigitta N.; Yuliani, Fara S.; Laiman, Vincent; Gondhowiardjo, Soehartati; Chuang, Hsiao-Chi
Narra J Vol. 5 No. 2 (2025): August 2025
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v5i2.1721

Lung cancer patients in Indonesia exhibit a high prevalence of epidermal growth factor receptor (EGFR) mutations, with a substantial proportion attributed to rare or uncommon variants. The clinical significance of rare EGFR mutations lies in their differential sensitivity to tyrosine kinase inhibitors (TKIs). While they are frequently resistant to first- and second- generation TKIs, they often respond to third-generation TKIs, necessitating tailored treatment options. The need for improving access to advanced targeted therapies in Indonesia also highlights the importance of conducting research on rare EGFR mutations. The aim of this study was to identify the spectrum and frequency of EGFR mutations in patients with lung adenocarcinoma in Indonesia. A cross-sectional observational study with total sampling was conducted from January 2016 to April 2024 to investigate EGFR mutation profiles in lung adenocarcinoma patients. Samples were acquired from patients with a confirmed anatomical pathology diagnosis from various healthcare centers across Indonesia. A total of 4,778 samples were analyzed using real-time quantitative polymerase chain reaction (RT-qPCR) on various specimen types to determine EGFR mutation prevalence and patterns. Associations between demographic data and EGFR mutation status were assessed. EGFR mutations were detected in 54.6% of samples, with common mutations (exon 19 deletions/insertions and point mutation L858R) comprising 76.2% of positive cases and rare mutations (exon 20 insertions, point mutation G719X, S768I, T790M, and L861Q) accounted for 20.3%. Significant associations were found between geographic origin, age, and sex with EGFR mutation status. This study confirms substantial genetic variability and geographical differences in EGFR mutations among Indonesian lung adenocarcinoma patients, emphasizing the urgent need for further research to prompt enhanced molecular diagnostics and targeted therapies in the region.

Co-Authors A. N. Kurniawan Agung Pranata Apriantoni, Riyan Arie Munandar Averdi Roezin Bangun Astarto Cholid Badri Chuang, Hsiao-Chi Evert D.C. Poetiray Gunawan, Andrew N. Halim, Brigitta N. Handoko Handoko Hawariy, Salik Henry Kodrat, Henry Heriyanto, Didik S. Ika Trisnawati, Ika Kahar Kusumawijaya Kotambunan, Charity Laiman, Vincent Lau, Vincent Lisnawati Rachmadi Maimun Syukri, Maimun Manuain, Donald Arinanda Marty Mawarpury Meryanne Elisabeth Nuryati C. Siregar Olivia Kuswanto Permata, Tiara Bunga Mayang Prajogi, Gregorius Ben Rachmad Suhanda Rafiq S. Nugroho Ratnawati Soediro Renaldi, Teuku Ria Kodariah Rima Novirianthy Sekarutami, Sri Mutya Tenggara, Jeffry B. Vito Filbert Jayalie, Vito Filbert Yuliani, Fara S. Zubairi Djoerban

Title

Found 7 Documents
Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title Search

Found 7 Documents Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title

Found 7 Documents
Search